Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.9 (
ribonuclease
)
6,589
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mammalian pancreatic ribonuclease (
RNase
) was conjugated chemically via a disulfide bond to human or murine
epidermal growth factor
(
EGF
). The conjugation between
EGF
and
RNase
was ascertained by SDS-PAGE using reduced and nonreduced conjugates. The
EGF
-
RNase
conjugate retained potent
RNase
activity and competed with 125I-
EGF
for binding to EGFR to the same extent as unconjugated
EGF
. Both the human and murine
EGF
-
RNase
conjugates showed dose-dependent cytotoxicity against EGFR-overexpressing A431 human squamous carcinoma cells with IC50 values of 3 x 10(-7) M and 6 x 10(-7) M, respectively, whereas free
RNase
had an IC50 of 10(-4) M. Against the EGFR-deficient small-cell lung cancer cell line H69, the
EGF
-
RNase
conjugate had no cytotoxic effect. The Human
EGF
-
RNase
conjugate showed dose-dependent cytotoxicity against other squamous carcinoma cell lines (TE-5, TE-1) and breast cancer cell lines (BT-20, SK-BR-3, MCF-7) and the cytotoxicity of the conjugate correlated positively with the level of expression of EGFR by each cell line. An unconjugated mixture of
EGF
and
RNase
had no greater effect than
RNase
alone on any cell line. Excess free
EGF
blocked
EGF
-
RNase
conjugate cytotoxicity against A431 cells. These results suggest that the
EGF
-
RNase
conjugate may be a more effective anticancer agent with less immunogenicity than coventional chimeric toxins.
...
PMID:Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin. 867 51
Proto-oncogenes are involved in the regulation of gene expression, for example after ligand binding to growth factor receptors. Expression of the proto-oncogenes c-fos, c-jun, c-ha-ras and c-myc was studied in in vivo grown and in vitro cultured bovine preimplantation blastocysts employing RT-PCR,
ribonuclease
protection assay and immunohistochemistry. Thirteen- and 14- day-old preimplantation blastocysts, i.e. stages before and during trophoblast elongation, were used. In in vivo-grown blastocysts c-fos, c-jun and c-ha-ras transcripts as well as c-Fos, c-Jun and c-Myc proteins were detected in all stages studied. Cultured blastocysts were treated with 10 nM
epidermal growth factor
and 10 nM transforming growth factor-alpha simultaneously. Epidermal growth factor and transforming growth factor-alpha treatment induced c-fos mRNA and c-Myc protein expression. The induction of downstream targets of the epidermal growth factor receptor by
epidermal growth factor
and transforming growth factor-alpha indicates a functional
epidermal growth factor
signal transduction pathway in elongating bovine blastocysts.
...
PMID:Expression of proto-oncogenes in bovine preimplantation blastocysts. 1083 31
Recombinant human
ribonuclease
1 (RNase 1) was chemically linked to recombinant human
epidermal growth factor
(
EGF
). The cytotoxicity of this conjugate was assayed using MTT assay. The
EGF
-RNase conjugate showed dose-dependent cytotoxicity against breast and squamous cell carcinomas overexpressing the EGF receptor (EGFR). The cytotoxicity of the conjugate correlated positively with the level of EGFR expression by each cell line. These results suggest that the
EGF
-RNase conjugate is a more effective anticancer agent with less immunogenicity and toxicity than conventional chimeric breast cancer toxins.
...
PMID:Molecular Targeting for Epidermal Growth Factor Receptor Expressed on Breast Cancer Cells by Human Fusion Protein. 1109 9
Expression of transforming growth factor alpha (TGFalpha), a member of the
epidermal growth factor
(
EGF
) family, is a general response of adult murine motoneurons to genetic and experimental lesions, TGFalpha appearing as an inducer of astrogliosis in these situations. Here we address the possibility that TGFalpha expression is not specific to pathological situations but may participate to the embryonic development of motoneurons. mRNA of TGFalpha and its receptor, the EGF receptor (EGFR), were detected by
ribonuclease
protection assay in the ventral part of the cervical spinal cord from embryonic day 12 (E12) until adult ages. Reverse transcription-PCR amplification of their transcripts from immunopurified E15 motoneurons, associated with in situ double-immunohistological assays, identified embryonic motoneurons as cellular sources of the TGFalpha-EGFR couple. In vitro, TGFalpha promoted the survival of immunopurified E15 motoneurons in a dose-dependent manner, with a magnitude similar to BDNF neuroprotective effects at equivalent concentrations. In a transgenic mouse expressing a human TGFalpha transgene under the control of the metallothionein 1 promoter, axotomy of the facial nerve provoked significantly less degeneration in the relevant motor pool of 1-week-old mice than in wild-type animals. No protection was observed in neonates, when the transgene exhibits only weak expression levels in the brainstem. In conclusion, our results point to TGFalpha as a physiologically relevant candidate for a neurotrophic role on developing motoneurons. Its expression by the embryonic motoneurons, which also synthesize its receptor, suggests that this chemokine is endowed with the capability to promote motoneuron survival in an autocrine-paracrine manner.
...
PMID:Transforming growth factor alpha: a promoter of motoneuron survival of potential biological relevance. 1154 18
<< Previous
1
2